Three Biotech Investment Ideas from Cormorant Asset Management
The biotech industry is regaining ground it lost in 2016 at full speed.
Cormorant Asset Management, headquartered in Massachusetts, specializes in the global healthcare sector. The firm offers investment management services to hedge funds and private equity vehicles, with a dedicated focus on healthcare, biotechnology, and life science industries across the United States.
Bihua Chen is the Founder of Cormorant Asset Management, LP, a distinguished investment firm specializing in innovative biotech, medtech, and life science companies, managing assets exceeding $3 billion. Before establishing Cormorant, Ms. Chen served as the manager of a healthcare-focused account, acting as a sub-adviser to a prominent multi-strategy hedge fund in New York. Ms. Chen's educational background includes a BS in genetics and genetic engineering from Fudan University, an MS in molecular biology from the Graduate School of Biomedical Science at Cornell Medical College, and an MBA from the prestigious Wharton School of Business.
Cormorant Asset Management serves 14 clients with discretionary assets under management totaling $4,022,479,936, as disclosed in their Form ADV dated March 30, 2024. In their latest 13F filing for Q4 2023, the firm reported holdings of $2,093,868,226 in managed 13F securities, with a top 10 holdings concentration of 62.79%. Notably, their largest holding is MoonLake Immunotherapeutics, with 8,494,151 shares held.
